^
    Back
    Association details:
    Biomarker:FGFR2-SORBS1 fusion
    Cancer:Cholangiocarcinoma
    Drug:Lytgobi (futibatinib) (FGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

    Excerpt:
    CONTRADICTING EVIDENCE: Secondary objectives included assessment of clinical PK, pharmacodynamics (PD), and preliminary antitumor activity of futibatinib….Confirmed PRs were observed in three patients with intrahepatic CCA (iCCA) harboring FGFR2–SORBS1 or FGFR2 BICC1 fusions (n = 2, 16-mg q.d. cohort; n = 1, 24-mg q.d. cohort)...
    DOI:
    https://doi.org/10.1016/j.annonc.2020.06.018
    Trial ID:
    FOENIX-CCA2
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma

    Excerpt:
    ...a 74-year-old female with recurrent FGFR2-SORBS1 fusion-positive ICC metastatic to her liver and lymph nodes. The patient subsequently received TAS-120, which resulted in a maximum response of −77%...After nearly 16 months on TAS-120, she had progression in all liver lesions.
    DOI:
    https://dx.doi.org/10.1158%2F2159-8290.CD-19-0182